PT1050301E - Composições medicinais contendo 2-amino-2-[2-(4- octilfenil)etil]propano-1,3-diol - Google Patents
Composições medicinais contendo 2-amino-2-[2-(4- octilfenil)etil]propano-1,3-diol Download PDFInfo
- Publication number
- PT1050301E PT1050301E PT99900351T PT99900351T PT1050301E PT 1050301 E PT1050301 E PT 1050301E PT 99900351 T PT99900351 T PT 99900351T PT 99900351 T PT99900351 T PT 99900351T PT 1050301 E PT1050301 E PT 1050301E
- Authority
- PT
- Portugal
- Prior art keywords
- octylphenyl
- diol
- amino
- propane
- ethyl
- Prior art date
Links
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 229920000858 Cyclodextrin Polymers 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 238000010322 bone marrow transplantation Methods 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Rheumatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10008045A JPH11209277A (ja) | 1998-01-19 | 1998-01-19 | 医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1050301E true PT1050301E (pt) | 2009-06-16 |
Family
ID=11682381
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT99900351T PT1050301E (pt) | 1998-01-19 | 1999-01-19 | Composições medicinais contendo 2-amino-2-[2-(4- octilfenil)etil]propano-1,3-diol |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1050301B1 (pt) |
| JP (2) | JPH11209277A (pt) |
| KR (1) | KR100546450B1 (pt) |
| CN (1) | CN1191062C (pt) |
| AT (1) | ATE426402T1 (pt) |
| AU (1) | AU1891199A (pt) |
| BR (1) | BR9907099A (pt) |
| CA (1) | CA2319217C (pt) |
| DE (1) | DE69940633D1 (pt) |
| ES (1) | ES2323199T3 (pt) |
| IL (1) | IL137362A (pt) |
| NZ (1) | NZ506408A (pt) |
| PT (1) | PT1050301E (pt) |
| RU (1) | RU2204387C2 (pt) |
| WO (1) | WO1999036065A1 (pt) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4627356B2 (ja) | 1999-06-30 | 2011-02-09 | 昭 松森 | ウイルス性心筋炎の予防または治療薬剤 |
| CA2421893A1 (en) | 2000-08-31 | 2002-03-07 | Merck And Co., Inc. | Phosphate derivatives as immunoregulatory agents |
| JP2007217438A (ja) * | 2001-07-17 | 2007-08-30 | Shionogi & Co Ltd | 注射用医薬製剤 |
| TWI232102B (en) * | 2001-07-17 | 2005-05-11 | Shionogi & Co | A pharmaceutical formulation for injection |
| GB0125443D0 (en) | 2001-10-23 | 2001-12-12 | Novartis Ag | Organic Compounds |
| EP1471054B1 (en) | 2002-01-11 | 2009-07-01 | Daiichi Sankyo Company, Limited | Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these |
| US20040014662A1 (en) | 2002-05-08 | 2004-01-22 | Per Lindquist | Modulation of neural stem cells and neural progenitor cells |
| DE602004017847D1 (de) * | 2003-04-08 | 2009-01-02 | Novartis Ag | Feste pharmazeutische darreichungsformen mit einem s1p rezeptoragonisten und einem zuckeralkohol |
| MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
| US7524887B2 (en) | 2003-06-06 | 2009-04-28 | Sanofi-Aventis Deutschland Gmbh | 2-amino-1,3-propanediol compounds for the treatment of acute pain |
| EP1484057A1 (en) * | 2003-06-06 | 2004-12-08 | Aventis Pharma Deutschland GmbH | Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain |
| KR20110136901A (ko) | 2004-02-24 | 2011-12-21 | 상꾜 가부시키가이샤 | 아미노 알코올 화합물 |
| RU2402324C2 (ru) * | 2004-07-30 | 2010-10-27 | Новартис Аг | Композиции на основе соединений 2-амино-1,3-пропандиола |
| DK2278960T4 (da) * | 2008-03-17 | 2020-01-27 | Actelion Pharmaceuticals Ltd | Dosisregimen til en selektiv sip1 receptoragonist |
| WO2011009634A2 (en) * | 2009-07-24 | 2011-01-27 | Ratiopharm Gmbh | Process for producing fingolimod salts |
| JO3177B1 (ar) * | 2011-04-01 | 2018-03-08 | Novartis Ag | تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول |
| DE102012101680A1 (de) * | 2012-02-29 | 2013-08-29 | Aicuris Gmbh & Co. Kg | Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat |
| US9925138B2 (en) | 2015-01-20 | 2018-03-27 | Handa Pharmaceuticals, Llc | Stable solid fingolimod dosage forms |
| WO2019167979A1 (ja) * | 2018-03-01 | 2019-09-06 | 石原産業株式会社 | 保存安定性に優れた医薬組成物 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS51133960A (en) * | 1975-05-16 | 1976-11-20 | Kao Corp | Defoaming method |
| JPS5718607A (en) * | 1980-07-07 | 1982-01-30 | Kaken Pharmaceut Co Ltd | Injection preparation |
| JPS58148816A (ja) * | 1982-02-27 | 1983-09-05 | Nippon Zenyaku Kogyo Kk | 低刺激性チアムリン注射剤 |
| JPS63253022A (ja) * | 1987-04-08 | 1988-10-20 | Nitto Electric Ind Co Ltd | バクロフエン外用製剤 |
| IE62095B1 (en) * | 1988-03-29 | 1994-12-14 | Univ Florida | Pharmaceutical formulations for parenteral use |
| EP0335545B2 (en) * | 1988-03-29 | 1998-09-23 | University Of Florida | Pharmaceutical formulations for parenteral use |
| JP3054776B2 (ja) * | 1990-04-13 | 2000-06-19 | 丸善製薬株式会社 | グリチルリチンの甘味抑制方法 |
| TW200402B (pt) * | 1990-08-13 | 1993-02-21 | Senju Pharma Co | |
| JPH0616547A (ja) * | 1992-07-01 | 1994-01-25 | Wakamoto Pharmaceut Co Ltd | 消炎点眼剤 |
| KR0155015B1 (ko) * | 1992-10-21 | 1998-12-01 | 고우야 마사시 | 2-아미노-1,3-프로판디올 화합물 및 면역 억제제 |
| JP2879395B2 (ja) * | 1992-10-26 | 1999-04-05 | 富士写真フイルム株式会社 | ロダシアニン化合物及びシクロデキストリンを含有する抗癌性組成物 |
| JPH07228532A (ja) * | 1993-04-22 | 1995-08-29 | Senju Pharmaceut Co Ltd | 水性液剤、その有効成分の溶解性向上方法および安定化方法 |
| JPH07316065A (ja) * | 1994-05-25 | 1995-12-05 | Fujisawa Pharmaceut Co Ltd | Ｆｒ９０１４６９物質製剤 |
| JP3870419B2 (ja) * | 1994-08-22 | 2007-01-17 | 三菱ウェルファーマ株式会社 | ベンゼン化合物およびその医薬としての用途 |
| JPH0859483A (ja) * | 1994-08-25 | 1996-03-05 | Higeta Shoyu Co Ltd | 抗真菌製剤 |
| JPH08175985A (ja) * | 1994-12-26 | 1996-07-09 | Lion Corp | 点眼剤 |
| PT812588E (pt) * | 1995-12-28 | 2005-01-31 | Mitsubishi Pharma Corp | Composicao farmaceutica externa para administracao topica contendo 2-amino-2-(2-(4-octilfenil)-etil)-propano-1,3-diol para o tratamento de doencas provocadas por uma afeccao imunitaria |
| JP2002241272A (ja) * | 1996-07-18 | 2002-08-28 | Mitsubishi Pharma Corp | 医薬処方組成物 |
-
1998
- 1998-01-19 JP JP10008045A patent/JPH11209277A/ja active Pending
-
1999
- 1999-01-19 AT AT99900351T patent/ATE426402T1/de active
- 1999-01-19 RU RU2000121989/14A patent/RU2204387C2/ru not_active IP Right Cessation
- 1999-01-19 BR BR9907099-5A patent/BR9907099A/pt not_active Application Discontinuation
- 1999-01-19 AU AU18911/99A patent/AU1891199A/en not_active Abandoned
- 1999-01-19 NZ NZ506408A patent/NZ506408A/xx unknown
- 1999-01-19 DE DE69940633T patent/DE69940633D1/de not_active Expired - Lifetime
- 1999-01-19 CN CNB998041645A patent/CN1191062C/zh not_active Expired - Fee Related
- 1999-01-19 ES ES99900351T patent/ES2323199T3/es not_active Expired - Lifetime
- 1999-01-19 IL IL13736299A patent/IL137362A/xx not_active IP Right Cessation
- 1999-01-19 WO PCT/JP1999/000152 patent/WO1999036065A1/ja not_active Ceased
- 1999-01-19 PT PT99900351T patent/PT1050301E/pt unknown
- 1999-01-19 CA CA002319217A patent/CA2319217C/en not_active Expired - Fee Related
- 1999-01-19 KR KR1020007007911A patent/KR100546450B1/ko not_active Expired - Fee Related
- 1999-01-19 JP JP2000539838A patent/JP4434486B2/ja not_active Expired - Lifetime
- 1999-01-19 EP EP99900351A patent/EP1050301B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1050301A4 (en) | 2004-11-17 |
| WO1999036065A1 (en) | 1999-07-22 |
| CA2319217C (en) | 2008-03-25 |
| JPH11209277A (ja) | 1999-08-03 |
| NZ506408A (en) | 2002-09-27 |
| IL137362A (en) | 2003-06-24 |
| RU2204387C2 (ru) | 2003-05-20 |
| AU1891199A (en) | 1999-08-02 |
| EP1050301A1 (en) | 2000-11-08 |
| IL137362A0 (en) | 2001-07-24 |
| ATE426402T1 (de) | 2009-04-15 |
| ES2323199T3 (es) | 2009-07-08 |
| KR100546450B1 (ko) | 2006-01-26 |
| JP4434486B2 (ja) | 2010-03-17 |
| CN1191062C (zh) | 2005-03-02 |
| DE69940633D1 (de) | 2009-05-07 |
| CN1294511A (zh) | 2001-05-09 |
| KR20010034240A (ko) | 2001-04-25 |
| BR9907099A (pt) | 2001-09-04 |
| CA2319217A1 (en) | 1999-07-22 |
| EP1050301B1 (en) | 2009-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1050301E (pt) | Composições medicinais contendo 2-amino-2-[2-(4- octilfenil)etil]propano-1,3-diol | |
| SI0990440T1 (sl) | Farmacevtski sestavek, ki obsega 2-amino-2-(2-(4-oktilfenil)etil)propan-1,3-diol, lecitin in saharid | |
| PT812588E (pt) | Composicao farmaceutica externa para administracao topica contendo 2-amino-2-(2-(4-octilfenil)-etil)-propano-1,3-diol para o tratamento de doencas provocadas por uma afeccao imunitaria | |
| BR9810312A (pt) | Composição farmacêutica que apresenta atividade antitumoral acentuada e/ou efeitos colaterais reduzidos contendo um agente antitumoral e um derivado do ácido hidroxìmico | |
| WO2002043750A8 (en) | Method for the stabilizing of biomolecules (e.g. insulin) in liquid formulations | |
| CA2304704A1 (en) | Formulations and methods for reducing toxicity of antineoplastic agents | |
| DE69828603D1 (de) | Verwendung von a-Glycosylceramiden zur Herstellung eines therapeutischen Mittelszur Behandlung von Autoimmunkrankheiten | |
| BR0008590A (pt) | Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto | |
| PT1002792E (pt) | Compostos de 2-aminopropano-1,3-diol, sua utilizacao medicinal e intermediariosda sintese dos mesmos | |
| BR0317747A (pt) | Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave | |
| ES2179910T3 (es) | Modificacion cristalina del cdch, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen. | |
| DE60000288D1 (de) | Monodisperse formulierungen, die hexamere acylierte insulinanaloge enthalten | |
| WO2001038303A3 (fr) | Analogues de la vitamine d | |
| BRPI0411503A (pt) | composto, composição farmacêutica, uso de um composto, método de tratar um ser humano que sofre de uma doença hiperproliferativa tal como cáncer, e, processo para a preparação de um composto | |
| BR0010983A (pt) | Preparações para a aplicação de agentes antiinflamatórios | |
| BR0311371A (pt) | Composições para uso terapêutico compreendendo uma vitamina, um sal de metal e insulina ou um hormÈnio de crescimento | |
| CA2340734A1 (en) | Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases | |
| BR9810452A (pt) | Nova combinação de medicamentos contra asma | |
| YU13599A (sh) | Primena farmaceutske kompozicije za dobijanje leka u obliku gela | |
| BR0011845A (pt) | Complexo farmacêutico | |
| BR0016646A (pt) | Método para tratar um paciente que sofre de dor, e, composição farmacêutica | |
| LT2006062A (lt) | Elementinės sieros vaistiniai produktai, skirti su glutationo s transferazės fermentu susijusioms ligoms gydyti | |
| TH25306A (th) | วิธีของการใช้สำหรับยับยั้งการสูญเสียกระดูกและการลดคอเลสเทอรอลในซีรัม | |
| GB2246954A (en) | Pharmaceutical anti-infective composition containing metronidazole | |
| BR9714774A (pt) | Pró-drogas solúveis de paclitaxel |